Creative Biolabs Highlights Three RNA Profiling Services for Cellular Heterogeneity Research

Creative Biolabs is highlighting three RNA research services, single-cell RNA sequencing, single-nucleus RNA sequencing and single-molecule fluorescence in situ hybridization, for laboratories studying cellular heterogeneity, the company said in a 24-7 Press Release dated November 11, 2026. The Shirley, NY-based contract research organization said the approaches address different questions and sample types.

How Creative Biolabs Matches RNA Methods To Samples

For studies involving viable, dissociated cells, the company's single-cell RNA sequencing service supports gene-expression analysis across individual cells. The workflow covers experimental planning, cell isolation, library preparation, sequencing and data analysis. The company said such studies can help identify distinct cell populations, characterize expression signatures and investigate heterogeneity in cancer, immunology and developmental biology.

For complex tissues, including brain specimens and samples that are difficult to dissociate, Creative Biolabs offers single-nucleus RNA sequencing. By analyzing isolated nuclei rather than intact cells, the approach can accommodate suitably preserved frozen tissues and reduce some dissociation-related biases, according to the company. Sample suitability still depends on the preservation method and the quality of the recovered nuclei.

The company said the methods are not directly interchangeable: whole-cell and nuclear RNA profiling capture different transcript populations, and tissue preservation, RNA integrity and research objectives influence the information obtained. Its single-molecule FISH analysis service uses fluorescently labeled oligonucleotide probes to detect selected RNA molecules in fixed cells, supporting investigation of transcript abundance and subcellular localization. Conventional smFISH typically examines preselected RNA targets and requires probe design, controls, imaging and image analysis.

Creative Biolabs' Research-Grade Service Portfolio

Creative Biolabs is a private contract research organization founded in 2014, according to akta.pro company records. The same records list a headcount range of 51-100 and a revenue estimate of $25 million-$50 million. The records describe proprietary platforms spanning phage display, hybridoma, bispecific engineering, CAR-T and lipid-based drug delivery, and note that 294 articles or patents have cited the company's services or products.

Earlier Creative Biolabs Service Launches

Creative Biolabs launched an integrated OMV and exosome-boosted CAR-T development platform for solid-tumor research, 24-7 Press Release reported in October 2026. The same outlet reported in October 2026 that the company highlighted its tumor organoid and immune cell co-culture services for studying CAR-T cell activity in 3D tumor models. FinancialContent Business Page reported in October 2026 that Creative Biolabs announced an integrated platform for oligonucleotide synthesis and PMO therapeutic development.

Creative Biolabs' Research-Use-Only Scope

Creative Biolabs said all three services are intended for research use only, not for diagnostic or therapeutic purposes. Researchers can share their sample type, preservation method and intended readouts with the company to discuss project feasibility and a suitable workflow, according to the release. The company's service pages describe its single-cell isolation, sequencing, multi-omics profiling, functional analysis and bioinformatics offerings.